It would seem MSB is a massively under valued stock by the valuation arguments above. I've said before we are sat on a number of call options with MSB. I'd certainly say a $20-30 million market cap would not be eventually beyond reason if they got approved for C-19 ARDS, why I was still so heavily invested in MSB at $5 before the trial was mucked up by the NIH. Its so binary. If they get approved on one application the others offer huge potential revenue propsects and a $60 million mkt cap perhaps not so unimaginable as it sounds.
I am on a US stem-cell company that is only phase II in a J&J partnership and has a $7 billion USD mkt cap. Novartis paertnerhsip another call option....
$90 a share on COVID ARDS Authorization ?, page-20
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
-0.065(4.47%) |
Mkt cap ! $1.587B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.39 | $2.865M | 2.047M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 164983 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 23268 | 23 |
View Market Depth
| Last trade - 13.45pm 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |